Payment overview · 2025
General Payments
$182.65
10 reported records · 6 companies
Healthcare provider profile · identity verified
Molly Brooks Gray, DO
Allopathic & Osteopathic Physicians|Family Medicine · COMANCHE, TX · NPI 1760641187
Verified facts
What the public records show
CMS Open Payments records show Molly Brooks Gray, DO received $182.65 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.79 | 24.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.43 | 18.9% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $34.37 | 18.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.28 | 16.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.55 | 11.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.23 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $182.65 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $44.79 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.28 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.28 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 384 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 80 |
| Furosemide | Furosemide | 325 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 60 |
| Gabapentin | Gabapentin | 282 | 56 |
| Losartan Potassium | Losartan Potassium | 257 | 64 |
| Potassium Chloride | Potassium Chloride | 257 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 49 |
| Lisinopril | Lisinopril | 180 | 53 |
| Sertraline Hcl | Sertraline Hcl | 161 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 40 |
| Omeprazole | Omeprazole | 147 | 34 |
| Tramadol Hcl | Tramadol Hcl | 140 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 39 |
| Trazodone Hcl | Trazodone Hcl | 137 | 25 |
| Buspirone Hcl | Buspirone Hcl | 125 | 22 |
| Eliquis | Apixaban | 121 | 19 |
| Jardiance | Empagliflozin | 116 | 12 |
| Metformin Hcl Er | Metformin Hcl | 114 | 21 |
| Carvedilol | Carvedilol | 112 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 28 |
| Montelukast Sodium | Montelukast Sodium | 107 | 26 |
| Spironolactone | Spironolactone | 97 | 27 |
| Donepezil Hcl | Donepezil Hcl | 93 | 16 |
| Meloxicam | Meloxicam | 92 | 21 |
| Metformin Hcl | Metformin Hcl | 90 | 25 |
| Azithromycin | Azithromycin | 88 | 68 |
| Allopurinol | Allopurinol | 86 | 22 |
| Divalproex Sodium | Divalproex Sodium | 85 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 19 |
| Levetiracetam | Levetiracetam | 76 | 14 |
| Mirtazapine | Mirtazapine | 71 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 70 | 18 |
| Pregabalin | Pregabalin | 68 | 13 |
| Memantine Hcl | Memantine Hcl | 63 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 62 | 13 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Ozempic | Semaglutide | 61 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 15 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Simvastatin | Simvastatin | 58 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 20 |
| Lorazepam | Lorazepam | 48 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 15 |
| Ibuprofen | Ibuprofen | 46 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 25 |
| Alprazolam | Alprazolam | 44 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Cephalexin | Cephalexin | 39 | 27 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 11 |
| Famotidine | Famotidine | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Prednisone | Prednisone | 35 | 27 |
| Glipizide | Glipizide | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 22 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Dexamethasone | Dexamethasone | 25 | 23 |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 15 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Novolin R | Insulin Regular, Human | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $182.65 · 10 records | Amgen Inc. | AIRSUPRA, Auvelity, KRYSTEXXA, Ozempic, Rybelsus, SKYCLARYS, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error